Education
About Us
Working with TipRanks
Follow Us
Almirall SA (GB:0O9B)
LSE:0O9B
0O9B Stock Chart & Stats
€12.90
-€0.04(-0.52%)
At close: 4:00 PM EST
€12.90
-€0.04(-0.52%)
Day’s Range― - ―
52-Week Range€8.74 - €13.98
Previous CloseN/A
Volume457.00
Average Volume (3M)2.60K
Market Cap
€2.97B
Enterprise Value€2.67B
Total Cash (Recent Filing)€376.60M
Total Debt (Recent Filing)€337.10M
Price to Earnings (P/E)137.8
Beta1.10
Next Earnings
May 11, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)0.09
Shares Outstanding214,785,200
10 Day Avg. Volume4,186
30 Day Avg. Volume2,602
Financial Highlights & Ratios
PEG Ratio-1.38
Price to Book (P/B)1.17
Price to Sales (P/S)1.77
P/FCF Ratio-2.62K
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
€14.00Price Target Upside8.53% Upside
Rating ConsensusHold
Number of Analyst Covering1
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Revenue GrowthConsistent revenue growth indicates Almirall's ability to expand its market presence and product adoption, supporting long-term business sustainability.
Strong Balance SheetA strong balance sheet with low leverage provides Almirall with financial stability and flexibility to invest in growth opportunities.
Operational EfficiencyHigh gross profit margins reflect effective cost management, which can enhance profitability and competitive positioning over time.
Bears Say
Low Net Profit MarginLow net profit margins can hinder Almirall's ability to generate sufficient returns for shareholders, impacting long-term financial health.
Declining Free Cash FlowDeclining free cash flow poses challenges for Almirall's financial flexibility, potentially limiting its capacity to fund new projects or manage debt.
Limited Return On EquityLow return on equity indicates that Almirall may not be effectively utilizing its equity base to generate substantial shareholder value.
Almirall News
0O9B FAQ
What was Almirall SA’s price range in the past 12 months?
Almirall SA lowest share price was €8.74 and its highest was €13.98 in the past 12 months.
What is Almirall SA’s market cap?
Almirall SA’s market cap is €2.97B.
When is Almirall SA’s upcoming earnings report date?
Almirall SA’s upcoming earnings report date is May 11, 2026 which is in 76 days.
How were Almirall SA’s earnings last quarter?
Almirall SA released its earnings results on Feb 23, 2026. The company reported €0.091 earnings per share for the quarter, missing the consensus estimate of €0.16 by -€0.069.
Is Almirall SA overvalued?
According to Wall Street analysts Almirall SA’s price is currently Undervalued.
Does Almirall SA pay dividends?
Almirall SA does not currently pay dividends.
What is Almirall SA’s EPS estimate?
Almirall SA’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Almirall SA have?
Almirall SA has 214,785,200 shares outstanding.
What happened to Almirall SA’s price movement after its last earnings report?
Almirall SA reported an EPS of €0.091 in its last earnings report, missing expectations of €0.16. Following the earnings report the stock price went down -5.821%.
Which hedge fund is a major shareholder of Almirall SA?
Currently, no hedge funds are holding shares in GB:0O9B
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Almirall Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Hold
Average Price Target:
€14.00 (8.53% Upside)
€14.00 (8.53% Upside)
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Positive
20 days / 200 days
Momentum
36.06%
12-Months-Change
Fundamentals
Return on Equity
1.45%
Trailing 12-Months
Asset Growth
-0.58%
Trailing 12-Months
Company Description
Almirall SA
Almirall, S.A., a biopharmaceutical company, engages in the research, development, manufacture, and sale of skin-health related medicines in Europe, the United States, and internationally. The company offers its products for dermatological diseases comprising actinic keratosis, atopic dermatitis, androgenic alopecia, psoriasis, onychomycosis, oncodermatology, acne, and orphan indications, as well as for cardiovascular, musculo-skeletal, respiratory, and nervous system; alimentary tract and metabolism; antiinfectives for systemic use; genito urinary system and sex hormones; immunostimulants; and systematic hormonal preparations. Its products include Ilumetri, Solaraze, Actikerall, Ciclopoli, Skilarence, Aczone, Decoderm, Cordran Tape, Azelex, Klisyri, Tazorac, Seysara, Veltin, Almax, Ebastel, Sativex, Crestor, and Efficib/Tesavel. Almirall, S.A. has collaboration and partnership agreements with Tyris Therapeutics, BIOMAP, the University of Dundee, Kaken Pharmaceutical Co Ltd., Ichnos Sciences Inc., the University Carlos III Madrid and MEDINA Foundation, 23andMe, Inc., HitGen Ltd., WuXi Biologics, Eli Lilly and Company, and Athenex, Inc. The company was formerly known as Laboratorios Almirall, S.A. and changed its name to Almirall, S.A. in May 2009. Almirall, S.A. was founded in 1943 and is headquartered in Barcelona, Spain.
0O9B Stock 12 Month Forecast
Average Price Target
€14.00
▲(8.53% Upside)
Technical Analysis
Faes Farma
―
Grifols
―
LABORATORIO REIG JOFRE
―
Laboratorios Farmaceuticos Rovi
―
Pharma Mar SA
―
Options Prices
Currently, No data available
---